1469MO Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trial
Hui‐Chuan Sun(Fudan University), Xiao‐Dong Zhu(Fudan University), Tianfu Wen(Sichuan University), D. Li(Henan Provincial People's Hospital), Jinhang Gao(Peking University), Yuqiao Zeng(Fujian Medical University), Xue Bai(Peking University), Xiaoxing Li(Sun Yat-sen University), Liu Lx(Anhui Provincial Hospital), Feixia Shen(Wenzhou Medical University), M. Kuang(Sun Yat-sen University), Yuzhu Wang(Chinese PLA General Hospital), Zhimei Huang(Tongji Hospital), Tao Peng(Chengdu University), Mingkai Chen(Jiangsu University), Baocai Xing(Peking University), Jun Zhou(Anhui Medical University), Jun Fan(Ministry of Education of the People's Republic of China), Tianqiang Song(Tianjin Medical University Cancer Institute and Hospital), J. Cai(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 3
Related Papers
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|977
Tyrosine Phosphorylation of Lactate Dehydrogenase A Is Important for NADH/NAD <sup>+</sup> Redox Homeostasis in Cancer Cells
|Molecular and Cellular Biology|2011|261
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
|The Lancet Oncology|2023|243
Liver diseases: epidemiology, causes, trends and predictions
|Signal Transduction and Targeted Therapy|2025|205
Prenatal anxiety and obstetric decisions among pregnant women in Wuhan and Chongqing during the COVID‐19 outbreak: a cross‐sectional study
|BJOG An International Journal of Obstetrics & Gynaecology|2020|187